{"name":"Altimmune","slug":"altimmune","ticker":"ALT","exchange":"NASDAQ","domain":"altimmune.com","description":"Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.","hq":"Gaithersburg, MD","founded":0,"employees":"57","ceo":"Vipin K. Garg","sector":"Obesity / NASH / Metabolic","stockPrice":3.4,"stockChange":0.02,"stockChangePercent":0.59,"marketCap":"$442M","metrics":{"revenue":41000,"revenueGrowth":420,"grossMargin":0,"rdSpend":66432000,"netIncome":-88093000,"cash":273456000,"dividendYield":0,"peRatio":-2.5,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"Tabegluo patent cliff ($0.0B at risk)","drug":"Tabegluo","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Pandemic Influenza Vaccine","genericName":"Pandemic Influenza Vaccine","slug":"pandemic-influenza-vaccine","indication":"Pandemic influenza prevention","status":"phase_3"}]}],"pipeline":[{"name":"Pandemic Influenza Vaccine","genericName":"Pandemic Influenza Vaccine","slug":"pandemic-influenza-vaccine","phase":"phase_3","mechanism":"A live attenuated intranasal vaccine that stimulates mucosal and systemic immune responses against pandemic influenza strains.","indications":["Pandemic influenza prevention"],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Altimmune Announces FDA Acceptance of Tabegluo NDA for Obesity","summary":"The FDA has accepted Altimmune's New Drug Application (NDA) for Tabegluo, a vaccine-based treatment for obesity.","drugName":"Tabegluo","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Altimmune Reports Third Quarter 2023 Financial Results","summary":"Altimmune reported its third-quarter 2023 financial results, which included revenue of $X.X million and a net loss of $X.X million.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQa1lhS3oxVnR6WllVNWs3SmRMYTZ5T3hNSTFoQmFELXAxZGFUeWttak53SkhDZTBKaHJzclNnWWtMZDZZREpCbDZRazRqVWpOZEN0RUxtUGFMNHhGblRTODVtd0d4Q3YxaUctbUhTUjAwdjRmQzNvX0tNTkVSQnNyQVVJaEpvWHltWmJXN1lHT25xZjJSSGRId3Q1a1FlMTh1dFF0QXZKdE4?oc=5","date":"2026-03-06","type":"pipeline","source":"Seeking Alpha","summary":"Altimmune Reports FY25 Financials: Why Is Big Pharma Staying Away (NASDAQ:ALT) - Seeking Alpha","headline":"Altimmune Reports FY25 Financials: Why Is Big Pharma Staying Away (NASDAQ:ALT)","sentiment":"neutral"},{"date":"2026-03-06","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOVUlJam1Id3ZHZWRMajZybXJZVUdFUUxVMU1pMmVrRlNLelgxZ2JMN0laQWhHdUxkNUVzNlc1bXhVTjVYdUcxcnRBZFotSnMwZ1JGNjg4amlvTHVrMW9uQnNKTVFzT2J2eWJYX3FsUFVHdXNxcGpVYXUxSGh1bm1WYmVIanQtQjM0anRkYmh5UkdWUUVua19tX2VQLTluZWtaNEtBcE13?oc=5","date":"2026-02-03","type":"trial","source":"Seeking Alpha","summary":"Altimmune Outlook: Where Pemvidutide Phase 3 Is Heading In 2026 (NASDAQ:ALT) - Seeking Alpha","headline":"Altimmune Outlook: Where Pemvidutide Phase 3 Is Heading In 2026 (NASDAQ:ALT)","sentiment":"neutral"},{"date":"2026-02-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-27","type":"regulatory","source":"simplywall.st","summary":"Altimmune (ALT) Valuation Check After Pemvidutide’s FDA Breakthrough Therapy Designation - simplywall.st","headline":"Altimmune (ALT) Valuation Check After Pemvidutide’s FDA Breakthrough Therapy Designation","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-25","type":"regulatory","source":"simplywall.st","summary":"Altimmune (ALT) Is Up 29.7% After FDA Breakthrough Tag for Pemvidutide in MASH Trial - simplywall.st","headline":"Altimmune (ALT) Is Up 29.7% After FDA Breakthrough Tag for Pemvidutide in MASH Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNeTlmMVlkNEpUd0JNQnpjVHRYQmotM0FJNVhiTjR0OTRJU1psbzZDTmhOTE5WU3pySzlSVEh1MUUyMFhzbTRRbWpKbjBtOGU4X2JlSkxxN2NPM3AwNVotOGFxV3RENG02UC14cEtpSHItYVhuTHhXMFo1VXBrZUtYOWE1cTktbDFSMHNBVGNQVTBSWHpMQlcxcExldi1xWnB2N3p1Z21ENERKMXdBM0hlWE9HS2hmUEtaeHc?oc=5","date":"2026-01-23","type":"pipeline","source":"24/7 Wall St.","summary":"Investor Bets $100k On David v Goliath Matchup With Altimmune and Eli Lilly - 24/7 Wall St.","headline":"Investor Bets $100k On David v Goliath Matchup With Altimmune and Eli Lilly - 24/7 Wall St.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPUjMwYjRIR2NOV1AxOEp2T3BCX3R1eC1MdVlpd1RSd3VhLXBRVFJuekZNYi1nVkVPR0o1a1dKR1RXY0lvNWo1bjNfVUZyRzJNck5mSV9kTjNqS0NTRW44dlFYeDM5aTFPWkhIU2tQcjFIcjdZSWJPeWFDLWR1QmdlYXduaGZWX1dJcjY1Y0dya2c0N3hxYXg1cG83eWpnV1FY?oc=5","date":"2026-01-06","type":"regulatory","source":"Finviz","summary":"ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH - Finviz","headline":"ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOYXR3Q1N4dV96ZklITFR2VHgxREZtVEZWeWRNYnlQZWVkVms3X3NhYWZOX3MxTmZRSk1yczJET3ZzbGxZZElKSWhLUW1KaHRwSTJIOS1SSGo2NVVGWE9BR3cwYlA1ZEN2d1lmRUNWWU44dU5PVlZzV0hKLWFjMzZHZW44elVZeWwzRFpodFZBMUdXdTRTbVRaRFNpVUdObEhsQVpHUmdtSGtRTWtQdlJ1dUM1dw?oc=5","date":"2026-01-05","type":"regulatory","source":"Stock Titan","summary":"FDA flags new liver disease drug for faster review after promising early data - Stock Titan","headline":"FDA flags new liver disease drug for faster review after promising early data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxQcnB4RDR0dGNqQnZtdDBvR3hwYklxVGJ5dC0zN2NqY256T2FQeG83NzVoMlZrMFFEeHRvZGRlenpEN19TTy1hQ3BKNVJlQVFzVm5sZzVhOVNpWHM1UTdqU0tZTF9WelNMNVhQbUphVmg0c0llOGRCZFFOQ2pjS3RzaGhwTDNDUkhYMmZaYnRVSVJIOWhuUjZ4aVQzLVdCay02Y05MV3czQzdkbVQ3d0E?oc=5","date":"2025-12-23","type":"trial","source":"Seeking Alpha","summary":"Altimmune: Pemvidutide's 48-Week Data Confirms The Market's Smokescreen - Seeking Alpha","headline":"Altimmune: Pemvidutide's 48-Week Data Confirms The Market's Smokescreen","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE55N011aF9hZEh0U1F2dWF1SFlGR1NzejJ4OS1DOWIzemJZN2JQVXRWLUU5M1hmc0NLNmVGOWNYSENtdjJBVjNTVzR5RzIwREU5dE5N?oc=5","date":"2025-12-19","type":"trial","source":"firstwordpharma.com","summary":"Altimmune touts new data for MASH hopeful, but investors sour - firstwordpharma.com","headline":"Altimmune touts new data for MASH hopeful, but investors sour","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPR0JtQUt1aWtDNUphTVNyVE44Y2hOZ1hVd3IwWHVzbUJ2VXlyR3FUMEhTa0JFMzhHeE92dnQxanliV2xCVUE2UndETzdXdTlldm5ZNVJQSlhaeU5jbXlKSG84a29pTFZGbEdOdmpQYUVId0l2TzZTcHZKV0p6M1hjZjZUOHZXaHhKLWJNamtGWDV5Tkd0TnZma2RjNmNmd0haZWdmSkJLQ0VySkNfVnBRc1dQY0I?oc=5","date":"2025-09-15","type":"pipeline","source":"Stock Titan","summary":"30-Year Pharma Veteran Linda Richardson Joins Altimmune as CCO to Lead Pemvidutide Commercialization - Stock Titan","headline":"30-Year Pharma Veteran Linda Richardson Joins Altimmune as CCO to Lead Pemvidutide Commercialization","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxPMkVzV1FsSXktbGxaTTNzSTJnX3pzcExfZ3F0YlRaLWhyM21iZW44TVVPaGJZNGZ6aTlYSGVGaFV3VjNtdk5sZ3lHNUpMNlpGVGZjQndUOEZzYjZ0WlVaTHpoSDU4RE0xa3JEemhrRXoxdkNMMjNfeU5aU0Q3enpVMXNVSDRDb3VsUjZtRENSN3lTVU1PdmJNWE9teHFCVnh6UW1GeWtIYk9vUXRBWTNPTXNVZU9qdTZlY05JTG9ESl9PdnpMTENZSW9YQ0pELVBVakRqMGtGOGs?oc=5","date":"2025-06-26","type":"trial","source":"reuters.com","summary":"Altimmune shares slump as weight-loss drug's fatty liver trial data disappoints - reuters.com","headline":"Altimmune shares slump as weight-loss drug's fatty liver trial data disappoints","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNTFZ0T2s2ZWJsLXZBUUxUUHdwSjhXVlhULUFSR2ZUS2stWjROdEkxcDlxbENTT0VYU19FSTRQUjliTXBiMzdRZHBOYVcxdm5iQ0lBY0VnTkF4RFk3RlRYZHNQZ2Q0Ykh6cHFoQWV2emh1T1NnRlVRWjFWU3ZHMGhxVDVITW1Ndw?oc=5","date":"2023-12-04","type":"trial","source":"Yahoo Finance","summary":"Altimmune (ALT) Rises 83% on Successful Phase II Obesity Study - Yahoo Finance","headline":"Altimmune (ALT) Rises 83% on Successful Phase II Obesity Study","sentiment":"positive"}],"patents":[{"drugName":"Tabegluo","drugSlug":"tabegluo","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Allergan","Novo Nordisk","Pfizer"],"therapeuticFocus":["Obesity","NASH","Metabolic Diseases"],"financials":{"source":"sec_edgar","revenue":41000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":41000,"period":"2025-12-31"},{"value":20000,"period":"2024-12-31"},{"value":20000,"period":"2024-12-31"},{"value":426000,"period":"2023-12-31"},{"value":426000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":66432000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-88093000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":279929000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":3.4,"previousClose":3.38,"fiftyTwoWeekHigh":7.73,"fiftyTwoWeekLow":2.87,"fiftyTwoWeekRange":"2.87 - 7.73","fiftyDayAverage":4.2,"twoHundredDayAverage":4.21,"beta":0.34,"enterpriseValue":201868544,"forwardPE":-2.5,"priceToBook":1.68,"priceToSales":10789.21,"enterpriseToRevenue":4923.62,"enterpriseToEbitda":-2.14,"pegRatio":0,"ebitda":-94377000,"ebitdaMargin":0,"freeCashflow":-38722124,"operatingCashflow":-67535000,"totalDebt":35688000,"debtToEquity":15.9,"currentRatio":18.55,"returnOnAssets":-28.2,"returnOnEquity":-50.6,"analystRating":"1.8 - Buy","recommendationKey":"buy","numberOfAnalysts":10,"targetMeanPrice":18,"targetHighPrice":28,"targetLowPrice":1,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":1484870400,"insiderHeldPercent":0.6,"institutionHeldPercent":42.5,"sharesOutstanding":130105177,"floatShares":129154290,"sharesShort":26485081,"shortRatio":8.53,"shortPercentOfFloat":20.4,"epsTrailing":-1,"epsForward":-1.36,"revenuePerShare":0,"bookValue":2.03,"officers":[{"age":57,"name":"Mr. Jerome Benedict Durso","title":"Chairman, CEO & President"},{"age":66,"name":"Dr. M. Scot Roberts Ph.D.","title":"Chief Scientific Officer"},{"age":62,"name":"Dr. Christophe  Arbet-Engels M.B.A., M.D., Ph.D.","title":"Chief Medical Officer"},{"age":69,"name":"Mr. Gregory L. Weaver CPA, M.B.A.","title":"Chief Financial Officer"},{"age":37,"name":"Mr. Andrew  Shutterly M.S.","title":"Principal Financial & Accounting Officer and Corporate Controller"},{"age":null,"name":"Mr. Bertrand  Georges Ph.D.","title":"Chief Technology Officer"},{"age":null,"name":"Mr. Tony  Blandin B.S.","title":"Vice President of Quality & Compliance Management"},{"age":61,"name":"Ms. Robin E. Abrams J.D.","title":"Chief Legal Officer & Corporate Secretary"}],"industry":"Biotechnology","irWebsite":"http://ir.pharmathene.com/phoenix.zhtml?c=191999&p=irol-irhome","website":"https://altimmune.com","phone":"240 654 1450"}}